Arden Eyes International Markets For Growth Of Namesake Brand
This article was originally published in The Rose Sheet
Executive Summary
Elizabeth Arden aims to grow its namesake beauty brand to a $1 billion business over the next several years through international expansion, according to President and CEO Scott Beattie
You may also be interested in...
Arden and Claiborne licensing agreement
Elizabeth Arden and Liz Claiborne strike exclusive, long-term global licensing agreement for the manufacture, distribution and marketing of Liz Claiborne fragrance brands, including Juicy Couture, Lucky Brand and Usher, firms announce May 28. Pact will award Arden improved market share and productivity in its North American fragrance business, efficiencies particularly within its fragrance supply chain and additional international business, among other benefits, according to E. Scott Beattie, chairman, president and CEO. Liz Claiborne CEO William L. McComb states: "For us to maximize profitability in [fragrance] going forward ... we would have to make significant changes to how [our business] is operated." With new licensing deal, Liz Claiborne "can continue to successfully develop and market brand-enhancing fragrances in a more capital-efficient manner, leveraging our strength in brand building with Arden's expertise in developing and growing fragrance businesses," McComb says. Liz Claiborne expects arrangement to positively impact 2008 cash flows; Arden says deal will contribute to sales and earnings growth in fiscal 2009...
Elizabeth Arden Preps Hilary Duff, Mariah Carey Scents; Q2 Sales Up Overseas
Wrapped with Love, a flanker for Elizabeth Arden's Hilary Duff franchise, as well as a limited edition Mariah Carey scent called Mariah Gold, will debut in prestige department stores in the second half of the fiscal year, the firm says
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.